IMMUNEXT INC has a total of 60 patent applications. It decreased the IP activity by 63.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ALDERBIO HOLDINGS LLC, MEDAREX LLC and TOLERX INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 14 | |
#2 | China | 5 | |
#3 | EPO (European Patent Office) | 5 | |
#4 | Australia | 3 | |
#5 | Canada | 3 | |
#6 | Israel | 3 | |
#7 | Republic of Korea | 3 | |
#8 | Mexico | 3 | |
#9 | Singapore | 3 | |
#10 | WIPO (World Intellectual Property Organization) | 3 | |
#11 | Brazil | 2 | |
#12 | Costa Rica | 2 | |
#13 | Peru | 2 | |
#14 | Chile | 1 | |
#15 | Colombia | 1 | |
#16 | Dominican Republic | 1 | |
#17 | Guatemala | 1 | |
#18 | Hong Kong | 1 | |
#19 | Morocco | 1 | |
#20 | Philippines | 1 | |
#21 | Tunisia | 1 | |
#22 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Analysing materials | |
#5 | Climate change adaptation technologies | |
#6 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Rothstein Jay | 49 |
#2 | Molloy Michael | 26 |
#3 | Hearn Arron | 15 |
#4 | Holgate Robert George Edward | 12 |
#5 | Powers Gordon | 12 |
#6 | Carriere Catherine | 12 |
#7 | Snyder Linda | 12 |
#8 | Pechenick Dov | 11 |
#9 | Gordon Marcia | 7 |
#10 | Lee Grace Ki Jeong | 7 |
Publication | Filing date | Title |
---|---|---|
WO2019136300A2 | Anti-mct1 antibodies and uses thereof | |
KR20190004718A | Anti-human VISTA antibodies and uses thereof | |
SG10201913431QA | Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy | |
CN107405398A | VSIG8 is identified as presumption VISTA acceptors and its to produce the purposes of VISTA/VSIG8 activators and antagonist |